

Could you help us develop a research trial for bladder cancer?

People with advanced muscle invasive either have an operation to remove their bladder (called cystectomy) or radiotherapy treatment. Radiotherapy allows people to avoid major surgery and keep their bladder. It is recommended to be given alongside treatments which increase cancer's sensitivity to radiation, either chemotherapy or breathing high dose oxygen (carbogen) and taking nicotinamide tablets. Carbogen and nicotinamide (CON) together increase the amount of oxygen in the tumour and may work best for people with low tumour oxygen levels (hypoxia).

The main question we would like to answer is "does giving people CON as well as chemotherapy and radiotherapy reduce the chance of their bladder cancer returning?". We would also like to explore whether the treatment works better for people with low tumour oxygen levels.



We would like to explore the thoughts and experiences of patients (and their families) to understand any concerns and hear their suggestions for answering this research question.

We are looking for patients (and/or family members) who have experience of radiotherapy treatment with either chemotherapy or CON for muscle invasive bladder cancer who are willing to join a discussion group.

The discussion group will be held online on one of the following dates, depending on which date works best for the people who are interested. If you would be interested but aren't able to make these times, please let us know.

- 10th March at 09:00-10:30
- 10th March at 13:30-15:00
- 13th March at 15:30-17:00

The group will include around five to ten contributors who will be reimbursed for their time.

No experience of taking part in research is required to join our discussion groups. We will provide background information and any other support people may need to be able to contribute.

There will be opportunities to remain involved in the project to continue to advise the researchers throughout the trial, which we expect to take around eight years to complete.



The trial is being developed by Prof Ananya Choudhury (The Christie NHS Foundation Trust, University of Manchester) and Dr Nuria Porta (Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR), a college of the University of London).

Introducing the trial team



Prof Ananya Choudhury
Clinical Oncologist at The
Christie NHS Foundation
Trust



Nuria Porta
Lead Statistician at the
ICR



Hannah Gribble
Senior Clinical Trial
Manager at the ICR

If you are interested in finding out more or would like to register to attend a discussion group, please contact Hannah at Hannah.Gribble@icr.ac.uk

Any contact details you provide will be stored securely according to the ICR's privacy policy (<https://www.icr.ac.uk/legal/privacy>). Details will be shared with researchers based at The Christie NHS Foundation Trust and the ICR and will only be used to arrange discussion groups and provide updates on this project.